Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
Related Questions
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
How would you manage a young premenopausal woman with hormone receptor-positive micrometastatic breast cancer in two axillary lymph nodes, but with only DCIS on breast surgical pathology?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
Would you avoid chemotherapy in a postmenopausal woman age >65 with T3 HR+/HER2 negative with Oncotype DX < 25?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
